1887

Abstract

Treatment of BALB/c mice with poly(A):poly(U) 18 h prior to infection with a lethal dose of murine cytomegalovirus (MCMV) increased survival. In parallel with increased survival, a 10- to 100-fold reduction of plaque-forming MCMV was found in the liver and spleen of mice 4 days post-infection with a sublethal dose of MCMV. Poly(A):poly(U) did not significantly increase natural killer cell activity or prolong the duration of elevated cytotoxic activity in infected animals. The possible role of interferon in the poly(A):poly(U)-induced protection of BALB/c mice is discussed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-73-9-2409
1992-09-01
2022-10-03
Loading full text...

Full text loading...

/deliver/fulltext/jgv/73/9/JV0730092409.html?itemId=/content/journal/jgv/10.1099/0022-1317-73-9-2409&mimeType=html&fmt=ahah

References

  1. Allan J. E., Shellam G. R. 1985; Characterization of interferon induction in mice of resistant and susceptible strains during murine cytomegalovirus infection. Journal of General Virology 66:1105–1112
    [Google Scholar]
  2. Balfour H. H. Jr 1990; Management of cytomegalovirus disease with antiviral drugs. Reviews of Infectious Diseases 12:S849–S860
    [Google Scholar]
  3. Bancroft G. J., Shellam G. R., Chalmer J. E. 1981; Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: correlation with patterns of resistance. Journal of Immunology 126:988–994
    [Google Scholar]
  4. Bukowski J. F., Woda B. A., Welsh R. M. 1984; Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. Journal of Virology 52:119–128
    [Google Scholar]
  5. Bukowski J. F., Warner J. F., Dennert G., Welsh R. M. 1985; Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo . Journal of Experimental Medicine 161:40–52
    [Google Scholar]
  6. Chalmer J. E., Mackenzie J. S., Stanley N. F. 1977; Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. Journal of General Virology 37:107–114
    [Google Scholar]
  7. Djeu J. Y., Heinbaugh J. A., Holden H. T., Herberman R. B. 1979; Augmentation of mouse natural killer cell activity by interferon and interferon inducers. Journal of Immunology 122:175–181
    [Google Scholar]
  8. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullet J., Mehalko S. G., Gordon S. M., Owen W. F. Jr, Matthews T. R., Buhles W. C., DeArmond B. 1990; Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. Journal of Infectious Diseases 163:716–719
    [Google Scholar]
  9. Grundy (Chalmer) J. E., Mackenzie J. S., Stanley N. F. 1981; Influence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection. Infection and Immunity 32:277–286
    [Google Scholar]
  10. Grundy (Chalmer) J. E., Trapman J., Allan J. E., Shellam G. R., Melief C. J. M. 1982; Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infection and Immunity 37:143–150
    [Google Scholar]
  11. Ho M. 1982; Human cytomegalovirus infections in immunosuppressed patients. In Cytomegalovirus: Biology and Infection pp 171–204 New York: Plenum Press;
    [Google Scholar]
  12. Jacobson M. A., Mills J. 1988; Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis and treatment. Annals of Internal Medicine 108:585–594
    [Google Scholar]
  13. Johnson A. G. 1979; Modulation of the immune system by synthetic polynucleotides. Springer Seminars on Immunopathology 2:149–168
    [Google Scholar]
  14. Jordan M. C. 1983; Latent infection and the elusive cytomegalovirus. Reviews of Infectious Diseases 5:205–215
    [Google Scholar]
  15. Kern E. R., Olsen G. A., Overall J. C. Jr, Glasgow J. A. 1978; Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycyticylic acid–poly-l-lysine complex. Antimicrobial Agents and Chemotherapy 13:344–346
    [Google Scholar]
  16. Lacour J., Lacour F., Spira A., Michelson M., Petit J.-Y., Delage G., Sarrazin D., Contesso G., Vigulier J. 1980; Adjuvant treatment with polyadenylic-polyuridylic acid (polyA: polyU) in operable breast cancer. Lancet ii:161–164
    [Google Scholar]
  17. Mercer J. A., Spector D. H. 1986; Pathogenesis of acute murine cytomegalovirus infection in resistant and susceptible strains of mice. Journal of Virology 57:497–504
    [Google Scholar]
  18. Odean M. J., Trachte G. J., Johnson A. G. 1991; Characterization of immune suppression induced by polyribonucleotides. International Journal of Immunopharmacology 13:339–348
    [Google Scholar]
  19. Osborn J. E. 1982; Cytomegalovirus and other herpesviruses. In The Mouse in Biomedical Research vol II pp 267–292 Edited by Foster H. L., Fox J. G., Small J. D. New York: Academic Press;
    [Google Scholar]
  20. Quinnan G. V. B., Manischewitz J. F. 1987; Genetically determined resistance to lethal murine cytomegalovirus infection is mediated by interferon-dependent and -independent restriction of virus replication. Journal of Virology 61:1875–1881
    [Google Scholar]
  21. Quinnan G. V. Jr, Kirmani N., Rook A. H., Manischewitz J. F., Jackson L., Moreschi G., Santos G. W., Saral R., Burns W. H. 1982a; Cytotoxic T cells in cytomegalovirus infection. New England Journal of Medicine 307:7–13
    [Google Scholar]
  22. Quinnan G. V. Jr, Manischewitz J. E., Kirmani N. 1982b; Involvement of natural killer cells in the pathogenesis of murine cytomegalovirus interstitial pneumonitis and the immune response to infection. Journal of General Virology 58:173–180
    [Google Scholar]
  23. Shanley J. D. 1990; In vivo administration of monoclonal antibody t6 the NK 1.1 antigen of natural killer cells: effect on acute murine cytomegalovirus infection. Journal of Medical Virology 30:58–60
    [Google Scholar]
  24. Shellam G. R., Allan J. E., Papadimitriou J. M., Bancroft G. J. 1981; Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proceedings of the National Academy of Sciences, U.S.A 78:5104–5108
    [Google Scholar]
  25. Snydman D. R. 1990; Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Reviews of Infectious Diseases 12:S839–S848
    [Google Scholar]
  26. Stevens J. G. 1989; Human herpesviruses: a consideration of the latent state. Microbiological Reviews 53:318–332
    [Google Scholar]
  27. Youn J. K., Hovanessian A. G., Riviere Y., Hue G., Lacour F. 1983; Enhancement of natural killer cell activity and 2-5A synthetase in mice treated with polyadenylic :polyuridylic acid. Cellular Immunology 79:298–308
    [Google Scholar]
  28. Youn J. K., Kim B. S., Min J. S., Lee K. S., Choi H. J., Lee Y. B., Lee D. W., Koh E. H., Kim K. W., Lee K. B., Michelson A. M. 1987; Adjuvant treatment of operable stomach cancer with polyadenylic :polyuridylic acid in addition to chemotherapeutic agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity. International Journal of Immunopharmacology 9:313–324
    [Google Scholar]
  29. Youn J. K., Kim B. S., Min J. S., Lee K. S., Choi H. J., Lee Y. B., Lee D. W., Park I. S., Roh J. K., Chung J. B., Koh E. H., Park Y. J., Kim H. I., Lee K. B. 1990; Adjuvant treatment of operable stomach cancer with polyadenylic: polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. International Journal of Immunopharmacology 12:298–295
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-73-9-2409
Loading
/content/journal/jgv/10.1099/0022-1317-73-9-2409
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error